Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inventurus Knowledge Solutions Ltd. (IKS.NS)
INR1,879.40
-24.00 (-1.26%)
IN NSE Healthcare Medical - Healthcare Information Services
Address
Building No. 5 & 6, Unit No. 801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airol 400708
Navi Mumbai, IN
Navi Mumbai, IN
CEO
Sachin K. Gupta
Website
ikshealth.com
IPO
2024-12-19
ISIN INE115Q01022
Also trades on
Bombay Stock Exchange · IKS.BO (INR)
National Stock Exchange of India · IKS.NS (INR)
Description
Inventurus Knowledge Solutions Ltd. specializes in providing medical coding, scribe support, and transcription services. The company's entire operation is dedicated to the healthcare sector, where it focuses on delivering solutions designed to optimize costs and enhance process efficiency for its clients. Founded on September 5, 2006, its corporate headquarters are situated in Thane, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,879.40
-24.00 (-1.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
277.1K
Beta
0.73
Float Shares
156.32M
Free Float %
93.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13% | -1.34% | +10.28% | +1.98% | +4.27% | +0.91% | +1.35% | -14.66% | -14.66% | -14.66% | -14.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,879.40
DCF (Unlevered)
3,861.66
+105.5%
DCF (Levered)
3,489.65
+85.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
13.09
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%+19.9% ★ Q1'26: +18.5% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+47.7% ★ Q1'26: +38.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+18.7% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+32.3% ★ Q1'26: +35.1% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+27.9% ★ Q1'26: +33.3% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.5% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.65× Q1'26: 0.56× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 9 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
26.64B
est: 24.65B (+8.1%)
|
32.36B
31.79B – 34.29B
+31.3% YoY
|
43.63B
40.31B – 45.43B
+34.8% YoY
|
54.98B
48.71B – 59.43B
+26.0% YoY
|
83.50B
75.45B – 88.73B
+51.9% YoY
|
93.70B
84.66B – 99.57B
+12.2% YoY
|
| EBITDA |
8.09B
est: 8.43B (-4.1%)
|
11.07B
10.88B – 11.73B
+31.3% YoY
|
14.93B
13.79B – 15.54B
+34.8% YoY
|
18.81B
16.67B – 20.34B
+26.0% YoY
|
28.57B
25.81B – 30.36B
+51.9% YoY
|
32.06B
28.97B – 34.07B
+12.2% YoY
|
| EBIT |
6.96B
est: 7.72B (-9.9%)
|
10.14B
9.96B – 10.74B
+31.3% YoY
|
13.67B
12.63B – 14.23B
+34.8% YoY
|
17.23B
15.26B – 18.62B
+26.0% YoY
|
26.16B
23.64B – 27.80B
+51.9% YoY
|
29.36B
26.52B – 31.20B
+12.2% YoY
|
| Net Income |
4.86B
est: 4.63B (+4.9%)
|
7.41B
7.28B – 7.55B
+60.0% YoY
|
8.69B
8.13B – 10.04B
+17.3% YoY
|
10.50B
9.48B – 12.21B
+20.8% YoY
|
12.75B
12.24B – 15.13B
+21.4% YoY
|
17.80B
15.57B – 19.25B
+39.6% YoY
|
| SGA |
3.99B
est: 1.59B (+150.3%)
|
2.09B
2.06B – 2.22B
+31.3% YoY
|
2.82B
2.61B – 2.94B
+34.8% YoY
|
3.56B
3.15B – 3.84B
+26.0% YoY
|
5.40B
4.88B – 5.74B
+51.9% YoY
|
6.06B
5.47B – 6.44B
+12.2% YoY
|
| EPS |
29.20
est: 27.90 (+4.7%)
|
43.56
42.88 – 44.43
+56.1% YoY
|
54.92
47.86 – 59.11
+26.1% YoY
|
68.31
55.84 – 71.87
+24.4% YoY
|
82.40
72.07 – 89.11
+20.6% YoY
|
104.80
91.66 – 113.34
+27.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.51B
OE per share TTM
8.92
Owner's Yield
0.54%
Maintenance CapEx ratio
4.24%
Maint CapEx / Avg PPE
6.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.37M
Shares Outstanding
167.62M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sachin K. Gupta | Founder, Chief Executive Officer & Non-Executive Director | 13M | male |
| Joseph Benardello | Co-Founder, Chief Growth Officer & Non-Executive Director | 320.0K | male |
| Christi Braun | Chief Legal & Compliance Officer | — | female |
| Erin Kennedy | Senior Vice President of Sales | — | female |
| Kathryn Weismantel | Chief Marketing Officer | — | female |
| Manisha Raghunath Kadagathur | Chief Human Resources Officer | — | female |
| Nithya Balasubramanian | Chief Financial Officer & Whole-time Director | — | female |
| Abhay Kumar Srivastava | EVP & Head of Leadership Effectiveness | — | male |
| Saransh Mundra | Associate Vice President of Investor Relations | — | male |
| Amit Saxena | Chief Information Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IKS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
